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Abstract
EVI1 (Ecotropic Viral Integration site I), which was originally identified as a myeloid transforming gene by means of retroviral
insertional mutagenesis in mouse leukemia, encodes a nuclear DNA binding zinc finger protein. The presence of zinc fingers
that are able to bind to specific sequences of DNA suggests that EVI1 is a transcriptional regulator; however, except a few,
target genes of EVI1 are poorly functionally identified thus far. In this study we provide evidence that EVI1 directly induces
the expression of Bcl-xL through the first set of zinc finger and thereby inhibits apoptosis. ChIP analysis showed that EVI1
binds to the Bcl-xL promoter in HT-29 cells, a colon carcinoma cell line, which expresses EVI1. The observation is also
supported by the fact that EVI1 siRNA treated HT-29 cells, shows a down regulation of Bcl-xL expression and that over
expression of EVI1 results in the induction of the Bcl-xL reporter construct. A set of EVI1 positive chronic myeloid leukemia
(CML) samples also showed higher Bcl-xL expression with respect to EVI1 negative samples. Interestingly, co-expression of
EVI1 with wild type, but not with dominant-negative form of PCAF, abolishes the effect of EVI1 on Bcl-xL, indicating that
acetylation of EVI1 abrogates its ability not only to bind Bcl-xL promoter but also alleviate Bcl-xL activity. Finally we have
shown that EVI1 expression regulates apoptosis in HT-29 cells, which is abrogated when HT-29 cells are transfected with
EVI1 siRNA or PCAF. The result for the first time shows a direct pathway by which EVI1 can protect cells from apoptosis and
also demonstrates that the pathway can be reversed when EVI1 is acetylated.
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Introduction
One of the genes associated with both murine and human
myeloid leukemia is EVI1 [1,2]. Over expression and aberrant
expression of EVI1 was shown to be associated with most forms of
human leukemia, as a consequence of chromosomal rearrange-
ments involving 3q26.2, where the gene is mapped [3] and also
without cytogenetically detectable rearrangements of the EVI1
locus as a result of unknown mechanism [2,4]. Overall up
regulation of EVI1 has been shown in 30% of advanced CML
patients, 8–10% of MDS –AML patients and 7.8% of de novo
AML cases [5–7]. Also studies indicate that EVI1 may be over
expressed in a subset of human colon cancers, and that EVI1
might affect disease progression and/or sensitivity to chemother-
apy [8]. The protein is highly conserved through evolution and
encodes a repressor and an activator domain with two sets of zinc
finger motifs [1,3,9,10]. Both zinc finger domains of EVI1
recognize and bind to specific DNA consensus sequence in vitro
and in vivo, of which some are characterized and some are not
functionally characterized [3,11,12]. Some known functionally
relevant targets of EVI1 includes Pbx1, calreticulin and GATA2
which are involved in calcium metabolism, maintenance of
adequate number of hematopoietic stem cells and self renewal
of hematopoietic stem cells [11,13,14]. However, the exact
mechanism by which EVI1 promotes cell proliferation and blocks
apoptosis still remains unclear.
Apoptosis is a critical process that is deregulated in oncogenesis
[15]. Bcl-2 and Bcl-xL are anti-apoptotic paralogues that inhibit
apoptosis which is elicited by a wide variety of stimuli, and play
critical roles in cancer development and resistance to treatment
whereas BAD, BAX, BID and PUMA enhance DNA damage
induced apoptosis [16]. Subtle changes in the cellular levels of Bcl-
xL expression can have dramatic phenotypes. Recently it was
shown that HIF-1a can directly up regulate Bcl-xL gene
transcription and can protect prostate cancer cells from apoptosis
[17]. Inducible expression of EVI1 or MDS1/EVI1 in the human
myelomonocytic cell line U937T lead to cell cycle arrest and
massive apoptosis upon exposure to differentiation stimuli, thereby
recapitulating salient aspects of the biology of MDS in vitro [18].
EVI1 activates PI3K/AKT signaling and suppresses TGF-b
mediated apoptosis [8]. This property of EVI1 appears likely to
be integral to its oncogenic potential, since loss of response to
apoptotic signals is one of the signs of transformation.
Posttranslational modification of proteins is a hallmark of signal
transduction and it allows existing proteins to react rapidly to extra
cellular events cascading to a total cellular response. These
modifications are tightly controlled in the cell because they are
involved in vital processes such as cell cycle progression,
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of EVI1 with different co-regulators could result in periodic,
reversible acetylation and deacetylation of EVI1 and assembly of
acetylated EVI1 in nuclear speckles [19]. The nuclear speckles are
associated with cellular functions such as DNA replication, gene
transcription and regulation of apoptosis. Evasion of apoptosis has
been observed in both EVI1 positive hematopoietic and epithelial
cells and suggests that EVI1 is a survival factor [8,20,21], however
none of them are mutually exclusive and additional mechanisms
mediating the survival promoting effects of EVI1 may also exist.
Here we show by several approaches that the first set of zinc finger
of EVI1 directly binds to the Bcl-xL promoter sequence both in
vitro and in vivo and directly modulates its function by activating the
anti-apoptotic gene and eventually blocks apoptosis. However
PCAF acetylated EVI1 reverses the function and renders the cell
towards apoptosis. These results point to a novel mechanism that
can be therapeutically utilized directly to prevent EVI1 mediated
block in apoptosis.
Materials and Methods
Cell Culture and Plasmids- The human embryonic kidney cell
line 293T, mouse fibroblast cell line NIH3T3 and human colon
cancer cell line HT-29 used in this study were cultured in
Dulbecco’s modified minimum essential medium supplemented
with 10% newborn calf serum (PAN Biotech, GmbH). Flag-EVI1-
wt was constructed by PCR cloning in EcoRI and SalI site of Flag-
pCMV vector (Sigma, USA) while pGL2 Bcl-xL (Bcl-xL promoter
in pGL2 vector) was a kind gift from Dr. Nunez, Michigan
University, USA. The Bcl-xL mutated promoter (Bcl-xL (Mut)) i.e.
without the EVI1 binding site was cloned in the luciferase vector.
EVI1 without either 1
st (EVI1- D 24 to 239, will be called as flag-
EVI1-DA) or 2
nd (EVI1- D 735 to 812, will be called as EVI1-DD)
set of zinc fingers were cloned by standard PCR method in EcoRI
and SalI site Flag-pCMV vector. All the constructs were verified
by sequencing and expression was checked by Western blotting.
Electrophoretic Mobility Shift Assay (EMSA) - Sequences of the
Bcl-xL promoter oligonucleotide probes that were used include
Bcl-xL, 59-CAGAATCTTATCTTGGCTTTGG-39 and the
probe with mutation in the binding site is: Bcl-xL-mut, 59-
CAGAATCTAATCATGGCTTTGG-39. For each probe, com-
plementary strands were synthesized, and equimolar concentra-
tions of complementary strands were annealed for use in EMSA.
Wild-type and mutated probes were labeled using c
32P-ATP with
T4 poly nucleotide kinase (Fermentas, Germany). For competition
assays, 306and 506unlabeled wild-type probes were used. The
human embryonic kidney cell line, 293T were harvested after
transfection with different constructs as mentioned in Figure 1B
and 3A. Nuclear extracts were prepared, and 10 mg of each was
incubated with 100 pmol of labeled probe in a 10-ml reaction
mixture (with 0.5 mg of poly dI: dC) (Sigma, USA) for 30 min at
room temperature. The mixture was electrophoresed at 4uCo na
6% non-denaturing PAGE for 3 h and signals were detected by
autoradiography.
Chromatin Immunoprecipitation- ChIP assay was carried out in
both HT-29 cells and 293T cells by using the Quik ChIP kit
(Imgenex India Pvt. Ltd, India). Briefly, as per the manufacturer’s
instructions only HT-29 cells or transfected 293T cells were cross
linked with 1% formaldehyde for 10 minutes. Cells were then
lysed, and nuclei were pelleted. The extract was sonicated,
supernatants were collected and treated with sheared salmon
sperm DNA and protein G agarose beads (Sigma, USA).
Immunoprecipitation was performed overnight at 4uC with 3 mg
of anti EVI1 antibody (Santa Cruz, USA) followed by protein G
agarose beads (Sigma, USA) and control IgG. Precipitates were
washed and extracted with 1% SDS and 0.1 M NaHCO3. Eluates
were pooled, heated and the purified DNA fragments were used as
template for PCR. The promoter-specific primers flanking the
binding site used were: Bcl-xL-F-AGGGTAAATGGCATGCA-
TATTAA and Bcl-xL-R-TTATAATAGGGATGGGCTCAAC-
CA (amplicon size-170 bp). We used a pair of non-specific primers
(EVI1-W) which were selected from a region that is approximately
1.27 kb upstream of the binding site, i.e., Bcl-xL-upstream-F-
CTCTCAGGAAGGTCTAGGGGGCG and Bcl-xL-upstream-R-
CGCCCCCGGGAGGGCTCCGGGGC (amplicon size-170 bp).
The same procedure was followed with 293T cells transfected with
empty Flag-pCMV vector, flag-EVI1-wt, flag-EVI1-DA and flag-
EVI1-DD and immunoprecipitated with anti-flag antibody (Sigma,
USA).
Si-RNA and Real-time Quantitative PCR- To knockdown the
expression of EVI1, specific EVI1 siRNA and its negative control
were transfected into HT-29 cells using the Icafectin siRNA
transfection reagent (Eurogentec, Belgium). Total RNA was
extracted from HT-29 cells, EVI1 siRNA transfected HT-29 cells
and siRNA negative control transfected HT-29 cells by using the
TRIzol reagent (Invitrogen, CA). The siRNA sequence that we
used was 59-39- CCA-CGA-AGA-ACG-GCA-AUA-U99. Com-
plementary cDNA was made by first strand cDNA synthesis kit
(Fermentas, Germany). PCR primers were designed from the Bcl-
xL mRNA reference sequence, NM_138578.1, which were as
follows: Bcl-xL forward-GCCACTTACCTGAATGACCAC, Bcl-
xL-reverse-TGGATGGTCAGTGTCTGGT (amplicon size-
210 bp). The Real-time PCR (RQ-PCR) master mix containing
SYBR Green (Eurogentec, Belgium) was used for real-time PCR
on Opticon 2.0 (MJ Research), and the data were recorded and
analyzed. Fold change of target genes (relative to b-actin) was
defined by 2
2DDCt, where DDCt=(Ct Bcl-xL2Ct b-actin for
EVI1 positive HT-29 or 293T cells)2(Ct Bcl-xL2Ct b-actin for
EVI1 negative HT-29 or 293T cells). Also RQ-PCR was used to
analyze the Bcl-xL expression in 293T cells transfected with CMV
vector control and flag-EVI1-wt construct. The same procedure
was followed with CML patient’s samples and is represented in
terms of relative Ct values. P value was calculated by using graph-
pad prism software, version 4.0.
Western Blot Analysis- 293T cells express the SV40 large T
antigen and were used for transfection assays by the calcium
phosphate precipitation method. After 48 h of transfection with
flag-EVI1-wt only and flag-EVI1-wt with either PCAF-wt or
PCAF-dominant negative (DN), cells were lysed by NP-40 based
lysis buffer (Tris-25 mM, NaCl-50 mM, NP-40-1%). Total protein
was resolved by SDS-polyacrylamide (Sigma, USA) gel electro-
phoresis and was electro blotted to polyvinylidene difluoride
membrane (Amersham Biosciences, USA). After blocking the
membrane with 5% nonfat milk (Biorad, USA) it was incubated
with different primary and secondary antibodies at room
temperature for 1 h and 40 minutes respectively. Signals were
detected by exposure to X-ray films after treatment with the
enhanced chemiluminescence (GE healthcare, USA). The primary
antibodies that were used are: Bcl-xL from Imgenex India Pvt.
Ltd., anti acetyl lysine antibody from cell signaling technology,
USA, anti-flag antibody from Sigma Aldrich Pvt. Ltd., USA and
secondary antibodies were from Santa Cruz Biotechnology, Santa
Cruz, CA. Western blot analysis was used to detect the presence/
absence of EVI1 in HT-29 cells and also HT-29 cells transfected
with EVI1 siRNA and its negative control.
Reporter Gene Assay-The reporter construct pGL2 Bcl-xL,
pGL2 Bcl-xL (mut) and the pRL-TK plasmid (Promega, USA)
containing the Bcl-xL promoter in pGL2, promoter lacking the
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respectively were used in dual reporter gene assay for studying
EVI1 dependent gene expression. 293T and NIH3T3 cells were
transfected with different constructs (mentioned in figure) by using
superfectamine (Qiagen, CA). Four hrs after transfection, the
medium was replaced by fresh medium containing serum. Twenty
four hrs after transfection, cells were treated with the lysis buffer
with three cycle of cell freezing and thawing. The samples were
immediately centrifuged, and luciferase activity was determined by
using Luminometer (GLOMAX 20/20, Promega, USA). All
measurements were done in triplicates, and the assays were
repeated three times in both 293T and NIH3T3 cells. The PCAF
siRNA used in this study was purchased from Sigma-Aldrich pvt.
Ltd, USA. The siRNA sequence that we used was 59-39- CUC-
UAA-UCC-UCA-CUC-AUU-U(dT)(dT). P value was calculated
by using graph-pad prism software, version 4.0.
Apoptosis Study- HT-29 cells were transfected with the EVI1
specific siRNA, PCAF and PCAF-DN separately as mentioned in
the Figure. After 24 h of transfection cells were treated with 1 mM
plumbagin (Sigma, USA) for 12 h in culture and then assayed for
apoptosis using the Annexin-V-PE & 7-AAD apoptosis detection
kit (BD Biosciences, USA). For annexin-V assay after staining with
Annexin-V-PE &7-AAD the cells were subjected to flow cytometry
analysis to detect the externalization of phosphatidyl serine (PS) on
cell membrane, a characteristic feature of apoptosis using FACS
calibur (BD Biosciences, USA). Apoptosis was also detected by
using the TUNEL assay for which after 12 h of treatment with
plumbagin, cells were harvested, fixed with 1% paraformaldehyde
Figure 1. EVI1 binds to Bcl-xL promoter element. A. A multiple sequence alignment of parts of Bcl-xL 2
nd exon from different species are shown
and the binding site is underlined. Genbank accession numbers of each of Bcl-xL sequence from different species that were used in the alignment
analysis are as follows, Canis familiaris: NM_001003072.1, Homo sapiens: NM_138578.1, Rattus rattus: NM_001033670.1, Gallus gallus:
NM_001025304.1, Danio rerio: NM_131807.1, Felis catus: NM_001009228.1, Bos taurus: NM_001077486.2 and Mus musculus: NM_009743.4. B. Nuclear
extracts from EVI1 transfected 293T cells were incubated with a radiolabelled, double-stranded oligo designed from the EVI1 binding site in Bcl-xL
promoter. EVI1 binds to Bcl-xL (lane 1) as shown by an arrow whereas a mutated probe failed to show any binding (lane 2). Lane 3 shows only the
empty vector transfected cells and lane 6 shows the probe without any nuclear lysate. Increasing amount of specific cold competitor at 306molar
excess of radiolabelled probe (lane 4) failed to inhibit the binding of EVI1 to Bcl-xL promoter however a cold competitor at 506molar excess of
radiolabelled probe (lane 5) inhibited binding of EVI1 to Bcl-xL promoter. C. ChIP analysis shows the occupancy of EVI1 on the Bcl-xL promoter in vivo.
After cross linking and chromatin fractionations DNA protein complexes were incubated with EVI1 antibody and the complex were processed as per
the manufacturer’s instructions (Imgenex India Pvt. Ltd.). Eluted DNA samples were then analyzed by PCR using specific primers flanking the EVI1
binding region. A band of 170 bp was observed only in HT-29 cells (lane 3) and no band was observed with IgG (lane 2) or with primers taken from
the upstream region (lane 6). Marker (M) and the input controls for both regions are as shown (lane 1 and lane 4). D. ChIP was performed on 293T
cells transfected with empty vector or EVI1 construct. For this assay flag-CMV-vector, flag-EVI1 wild type (Wt), flag- EVI1-DA (EVI1-D24 to 239) and
flag-EVI1-DD (EVI1-D735 to 812) constructs were transfected separately in 293T cells. After processing as described above PCR showed an
amplification of 170 bp when cells were transfected with EVI1 and EVI1-DD where as no amplification was observed in vector transfected cells or
EVI1-DA transfected cells. Marker and the input control are as shown.
doi:10.1371/journal.pone.0025370.g001
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ethanol at 220uC. After 18 hr of storage at 220uC the cells were
washed with PBS and subjected to TUNEL staining using the
APO Direct Kit supplied by BD Biosciences and analyzed by flow
cytometer.
Results
EVI1 binds to Bcl-xL promoter both in vitro and in vivo
through the 1
st set of zinc finger
Although several authors have shown evasion of apoptosis in
both EVI1 positive hematopoietic and epithelial cells suggesting
that EVI1 is a survival factor, none of them have shown a direct
relation between EVI1 and any of the apoptosis regulators. To
know if EVI1 directly regulates apoptosis we bioinformatically
(www.cbrc.jp/research/db/TFSEARCH.html) scanned a set of
both pro-and anti- apoptotic reference gene sequences for EVI1
binding sites and found that Bcl-xL promoter contains a
characteristic motif for the binding of EVI1. A sequence of
‘‘TTATCTTGGCT’’ in the non-coding region of 2
nd exon,
113 bp upstream of the start codon showed a score of 89 (default
score is 85). Also inspection of the same sequence revealed a
similar result with MATINSPECTOR (0.89) (www.genomatix.de)
and TRANSFAC (0.886) (www.biobase-international.com). Most
interestingly the same region was previously shown to be a target
of GATA1 and EVI1 by computational analysis in mouse Bcl-xL
promoter [22]. Studies have shown earlier that the homology
between rat, mouse and human Bcl-xL gene is extremely high
across the region encompassing exons 1B through to exon 3 [23].
We also found that the identified region is almost conserved across
species (Figure 1A). This finding suggests that Bcl-xL could be a
direct transcriptional target of EVI1 which is conserved among
species. To examine if EVI1 can bind to the site of the Bcl-xL, we
performed a gel shift assay using a radio labeled DNA probe
covering the region from 285 to 2120 with respect to the start
codon of the Bcl-xL sequence. The incubation of this probe with
nuclear extracts from 293T cells ectopically expressing EVI1
showed a DNA-protein complex (Figure 1B, lane 1) while no such
binding was observed with only 293T cells (lane 3). The complex
was not observed with a mutated Bcl-xL oligomer (lane 2).
Increasing amount of specific cold competitor at 306molar excess
of radiolabelled probe failed to inhibit the binding of EVI1 to Bcl-
xL promoter (lane 4) however a cold competitor at 506 molar
excess of radiolabelled probe inhibited the binding of EVI1 to Bcl-
xL promoter probe (lane 5). Thus we conclude that EVI1 binds in
vitro to the Bcl-xL promoter.
To determine whether EVI1 binds directly with this region in
vivo, we used chromatin immunoprecipitation (ChIP) assay in HT-
29 cells, a colon carcinoma cell line, which expresses EVI1. After
cross linking and chromatin fractionations the DNA-protein
complex was immunoprecipitated with EVI1 antibody (Santa
Cruz biotechnology, USA) and control IgG. DNA-protein
complexes were processed as per the manufacturer’s instructions
(Imgenex India Pvt. Ltd., India). Eluted DNA samples were then
analyzed by PCR using both a set of specific primers flanking the
binding region and also a set of non-specific primers that was
selected from a region upstream of the binding site. We observed
occupancy of EVI1 at the Bcl-xL promoter, whereas no signal was
amplified from the IgG immunoprecipitated negative control. No
signal was also observed when primers (EVI1-W) from another
region were selected that does not contain a putative EVI1 binding
sequence (Figure 1C). EVI1 contains two set of zinc finger
domains and to understand which set of zinc finger actually binds
to the Bcl-xL promoter we transfected either empty vector or
EVI1-wt or EVI1-DA or EVI1-DD separately in 293T cells and
checked them in ChIP assay. It was observed that EVI1-wt and
EVI1-DD binds to Bcl-xL whereas EVI1-DA failed to bind the
same region (Figure 1D). Thus, EVI1 binds to the sequence
identified in the Bcl-xL promoter both in vitro and in vivo and Bcl-
xL joins a group of genes whose promoter is targeted by EVI1.
Binding of EVI1 up regulates Bcl-xL transcriptional
activity
To accurately quantify the Bcl-xL expression we used real-time
PCR assay with RNA extracted from HT-29 cells and also HT-29
cells transfected with a specific EVI1 siRNA and a negative
control. Considerable down regulation of EVI1 expression was
observed in HT-29 cells treated with EVI1 siRNA (Figure 2A-left
panel). By down regulating EVI1 by specific EVI1 siRNA we
found that Bcl-xL was also down regulated by almost 5 times
(Figure 2A). Negative control siRNA transfected cells didn’t show
any change. The data was normalized to the endogenous
expression of b-actin. We also found that Bcl-xL was up regulated
almost 5.07 fold in EVI1 transfected 293T cells with respect to
normalized vector control (Figure 2B). This up regulation of Bcl-
xL mRNA was also reflected in the levels of BCL-XL protein
expression (Figure 2C). Our laboratory works on CML disease
progression using CML patient samples (with approval from
human ethical committee). As EVI1 is known to be up regulated in
CML disease progression we tested all our samples for EVI1
positivity. In this study we statistically showed that Bcl-xL
transcriptional activity is different in CML samples depending
on the presence or absence of EVI1. EVI1 positive samples
showed a significantly more Bcl-xL expression than the EVI1
negative samples (Figure 2D).
To further clarify the transcriptional regulation of EVI1 binding
to Bcl-xL, we did a luciferase assay using a mouse Bcl-xL reporter
construct, pGL2-Bcl-xL (kind gift from Gabriel Nunez, University
of Michigan Medical School, Ann Arbor, Michigan) which covers
3.2 kb upstream from the Bcl-xL start codon in both 293T and
NIH3T3 cells. It was already reported earlier that the EVI1
binding site is same in human and mouse (Figure 1A). The EVI1
transfected cells showed a significantly higher luciferase activity
(5.81 fold) than the vector transfected cells (Figure 2E, 2
nd bar).
Mutation in the EVI1 binding region failed to activate the
promoter (Figure 2E, bar 6 with respect to bar 5). The assay result
is a mean of three independent experiments. We also found a
significant increase in the activity with EVI1-DD where as no such
change was observed with EVI1-DA (Figure 2E, bar 3 and 4)
hence corroborating the ChIP data that the first set of zinc finger
binds to Bcl-xL promoter and up regulates its activity. Bioinfor-
matics analysis has earlier shown that the same site is also occupied
by the GATA1 transcription factor [22]. The role of GATA1 in
Bcl-xL expression has been obscure because mutations in the
typical GATA binding site did not affect GATA1 activated Bcl-xL
transcription [24]. However contrasting report states that GATA1
binds to the GATT motif (404 bp or 408 bp upstream of the
translation start site in mouse and human Bcl-xL promoters) and
mutation of the site shows deregulation of Bcl-xL function [25]. As
mutation in the GATA1 binding site (408 bp upstream of the
translation start site) down regulates Bcl-xL so the bioinformati-
cally gathered GATA1 site [22] 113 bp upstream of the
translation start site may not be active. It is possible that EVI1
directly binds to the region 113 bp upstream of the start codon
and GATA1 binds to EVI1 at this site to give a delayed kinetics of
Bcl-xL induction as it has been shown that both the proteins
interact with each other [26]. Again to rule out the possibility that
GATA1 binds to the same region we also used NIH 3T3 cells
Regulation of Bcl-xL by EVI1
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Bcl-xL promoter activity (Figure 2F). Thus all of the above shows
that EVI1 directly binds to the Bcl-xL promoter through its
proximal set of zinc finger and in the process can regulate its
activity.
Acetylated EVI1 abrogates Bcl-xL promoter binding and
down regulates its transcriptional activity
Posttranslational-modifications, mainly acetylation of non-
histone proteins show’s differential transcriptional activity, includ-
ing both positive and negative effects on DNA binding affinity.
Earlier we have shown that the proto-oncogene EVI1 was
acetylated in vivo [19]. Since studies have shown that reversible
acetylation of EVI1 are associated with nuclear speckles and
nuclear speckles are known to be associated with different cellular
functions including apoptosis we wanted to know if acetylated
EVI1 has any role on Bcl-xL DNA binding, transcriptional activity
and eventually apoptosis. Here we found by EMSA that the
incubation of the Bcl-xL probe with nuclear extracts from 293T
cells transfected with both EVI1 and PCAF abolished EVI1 DNA
binding (Figure 3A, lane 2) with respect to nuclear extracts from
cells transfected with EVI1 only (Figure 3A, lane 1). To
understand whether protein-protein interaction between EVI1
and PCAF abolishes the binding of EVI1/PCAF complex to Bcl-
xL or it is acetylation of EVI1 by PCAF that is abolishing the
binding of the complex we used a dominant negative form of
PCAF (PCAF-DN). It was shown earlier that a dominant negative
form of PCAF fails to acetylate either histones or other proteins.
Interestingly the DNA binding was again observed when nuclear
extracts from cells transfected with EVI1 and PCAF-DN was used
Figure 2. EVI1 induces Bcl-xL promoter trans-activity. A. HT-29 cell line was transfected with EVI1 siRNA and its negative control. After 24 h of
transfection total RNA was isolated by TRIzol reagent (Invitrogen). Complementary DNA (cDNA) was prepared using oligodT (Fermentas, Germany)
and subsequently RQ-PCR was performed with primers Bcl-xL-F-GCCACTTACCTGAATGACCAC, Bcl-xL-R-TGGATGGTCAGTGTCTGGT with SYBR green
gold real time master mix (Eurogentec, Belgium). b-actin primers were used on the same sample for normalization. Bcl-xL level went down by 5.02
fold for siRNA transfected cells as compared to normal cells (p value=0.0141). The left panel showed the expression of EVI1 protein level. siRNA
negative control neither showed any change in Bcl-xL mRNA level nor in EVI1 protein level as compared to only HT-29 cells. B. Bcl-xL mRNA was up
regulated in EVI1 transfected cells. 293T cells transfected with only empty vector or EVI1 were processed as described above. The EVI1-positive cells
showed 5.07 fold more Bcl-xL expression in comparison to normalized vector control (p value=0.047). C. Total protein was isolated from 293T cells
transfected with only vector or with EVI1 and checked for BCL-XL protein level by standard Western blotting by using anti-Bcl-xL antibody (Imgenex
India Pvt. Ltd). D. EVI1 positive (n=13) and negative cases (n=10) of CML patients were checked for Bcl-xL mRNA by RQ-PCR as described above. The
EVI1 positive cases showed an up regulation of Bcl-xL compared to EVI1 negative cases. (P value=0.0001). E. 293T cell line was transfected with either
empty vector or EVI1 along with the pGL2-Bcl-xL promoter or pGL2 Bcl-xL (mut) and renilla luciferase (internal control). Twenty four hours later the
cells were lysed and luciferase activity was measured using the luminometer (GLOMAX 20/20, Promega). EVI1 up regulated the Bcl-xL promoter
activity by 5.81 fold and not the mutated promoter. Also EVI1-DD up regulated the wild type promoter by 5.68 fold and not EVI1-DA. The results were
expressed as mean 6 s.e. of triplicate experiments, which are representative of three different assays (p value,0.0001). F. NIH3T3 cell line was
transfected with either empty vector or EVI1 along with the pGL2-Bcl-xL promoter and renilla luciferase (internal control). Luciferase activity was
measured as described above. EVI1 up regulated the Bcl-xL promoter activity by 3.6 fold in NIH3T3 cells (p value=0.0066).
doi:10.1371/journal.pone.0025370.g002
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with PCAF or PCAF-DN was shown by Western blot using an
anti-acetyl lysine antibody (Figure 3B, upper panel). The same blot
was stripped and reprobed with anti-flag antibody to show the
expression of EVI1 and PCAF/PCAF-DN (Figure 3B, lower
panel). We also wanted to know if acetylation/deacetylation of
EVI1 and the reduced binding to Bcl-xL also affects the
transcriptional activity. Unlike the previous work where acetylated
EVI1 activated the synthetic promoter [19] here we found that
PCAF acetylated EVI1 reduced Bcl-xL transcriptional activity
with respect to wild type EVI1 in 293T cells (Figure 3C). However,
when PCAF-DN was used with EVI1, the Bcl-xL transcriptional
activity was higher (almost identical to wild type EVI1 alone)
(Figure 3C). PCAF and PCAF-DN didn’t show any activity on the
Bcl-xL promoter element. To check whether endogenous PCAF
has any role, PCAF siRNA was used and a further up regulation of
the Bcl-xL promoter element was observed which proves that
PCAF mediated acetylation of EVI1 down regulates Bcl-xL
transcriptional activity (Figure 3C). The above result was
substantiated when increasing concentration of PCAF dramati-
cally decreased the EVI1 mediated up regulation in a dose
dependent manner (Figure 3D). Thus acetylation can regulate
EVI1 downstream gene transcription in cells by blocking EVI1-
Bcl-xL DNA binding activity.
Acetylation of EVI1 induces apoptosis in HT-29 cells
EVI1 blocks cell death by selectively binding and inhibiting
JNK and also EVI1 specifically represses the IFN-dependent
induction of the tumor suppressor PML and blocks the apoptotic
pathway activated by PML [21,27]. In addition to the ability to
inhibit Smad-mediated signaling, EVI1 also functions as a survival
gene by activating an anti-apoptotic P13K/AKT signaling
Figure 3. Acetylated EVI1 deregulates Bcl-xL binding and transactivation. A. Nuclear extracts from EVI1-wt or EVI1-wt+PCAF-wt or EVI1-
wt+PCAF-DN transfected cells were incubated with a radiolabelled, double-stranded oligo containing the wild type Bcl-xL EVI1 site and analyzed by
EMSA. EVI1 binds to Bcl-xL in vitro (as shown earlier) (lane 1). However, acetylated EVI1 (EVI1+PCAF-wt) failed to bind the Bcl-xL probe (lane 2). The
binding was observed again when EVI1 was transfected along with PCAF-DN (lane 3). B. The same nuclear extract was electrophoresed on a SDS-
PAGE and transferred to a PVDF membrane which was subsequently probed with the anti acetylated lysine antibody (Cell Signaling Technology,
USA). Acetylated band of EVI1 was observed only when EVI1 was transfected along with PCAF (upper panel, lane 3) whereas no acetylated band was
observed when EVI1 was transfected alone (upper panel, lane 2) or with PCAF-DN (upper panel, lane 4). The same blot was stripped and reprobed
with the anti-flag antibody (Sigma). Expression of EVI1, PCAF and PCAF-DN was observed as shown on the figure (lower panel). Lane 1 showed the
only empty vector transfected nuclear extract. C. 293T cells were transfected with constructs as mentioned in the figure along with the promoter
construct and renilla luciferase (as an internal control). Twenty four hours later the cells were lysed and luciferase activity was measured using the
luminometer. Up regulation of Bcl-xL was blocked when cells were transfected with both EVI1 and PCAF-wt; however the block was released when
cells were transfected with EVI1-wt and PCAF-DN. Only PCAF-wt and PCAF-DN showed no effect on the promoter activity. The respective fold change
with respect to vector for EVI1-wt, Vector with PCAF siRNA, EVI1 with PCAF siRNA, EVI1-wt with PCAF-wt, EVI1-wt with PCAF-DN, PCAF-wt and PCAF-
DN are 2.72, 1.18, 4.14, 1.052, 2.89, 1.20 and 1.046 (p value,0.0001). D. 293T cells were transfected with vector and EVI1 with increasing
concentrations of PCAF (1 mgt o5mg) with the promoter construct and renilla luciferase. Luciferase assay was done as described above. Up
regulation of Bcl-xL was blocked by PCAF in a dose dependent manner (p value,0.0001).
doi:10.1371/journal.pone.0025370.g003
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colon cancer cells. To examine the potential role of EVI1 in
salvaging the cells from apoptotic death, by external stimuli, we
performed apoptosis assay in HT-29 cells. Earlier apoptosis assay
was shown in HT-29 cells by using taxol [8], however we have
used plumbagin as plumbagin has no effect on PCAF mediated
acetylation in vivo [28]. EVI1 siRNA was used for a set of cells to
down regulate the expression of EVI1. Cells were treated in
duplicate with plumbagin for 12 h in culture and then assayed for
apoptosis using the Annexin-V-PE & 7-AAD apoptosis detection
kit. After staining with Annexin-V-PE & 7-AAD the cells were
subjected to flow cytometry analysis to detect the externalization of
phosphatidyl serine (PS) on cell membrane, a characteristic feature
of apoptosis. As shown in Figure 4A, HT-29 cells showed reduced
apoptosis with respect to cells that express the EVI1 siRNA
suggesting a direct protective role of EVI1 from apoptotic death of
cells. It is becoming increasingly apparent that acetyltransferases
act as mediators of environmental signals that can dictate the
commitment to cell growth, differentiation or apoptosis. Here we
found that acetylation of EVI1 by PCAF increased apoptosis
which was again decreased when PCAF-DN was used confirming
that here acetylated EVI1 failed to bind Bcl-xL and hence was not
able to up regulate its activity (Figure 4A). As noted earlier in
Figure 2C all of the transfection showed a substantial change in
the regulation of BCL-XL protein expression (Figure 4B) con-
firming that EVI1 is directly regulating Bcl-xL.
The same transfections were carried out again and after
treatment with plumbagin cells were stained with TUNEL reagent
and assayed with flow cytometry. As shown in Figure 5A apoptosis
increased when cells were transfected with EVI1 siRNA or PCAF
while PCAF-DN showed no effect. The same cells were analyzed
for Bcl-xL both at transcript level (Figure 5B) and protein level
(Figure 5C). Figure 5B showed that Bcl-xL activity went down
when HT-29 cells were transfected with either EVI1 siRNA or
PCAF. Also the same trend was seen in the protein level of BCL-
XL (Figure 5C). The western blotting data was quantified by using
Bio-rad gel documentation system volume analysis method for the
quantification of Bcl-xL with respect to the beta actin (Figure 5D).
Discussion
Apoptosis, triggered by a variety of intra- and extra cellular
signals, is important for normal development, to maintain tissue
homeostasis, and as a defense strategy against the emergence of
cancer [29,30]. However, alterations in the relative level of
intracellular pro- versus anti-apoptotic Bcl-2 family proteins are
implicated in tumorigenesis in both clinical cases and transgenic
models [31]. Clinical studies that demonstrated increased level of
Bcl-xL in breast carcinoma, gastric cancer cells and others are
associated with a poor outcome. In addition, these members are
also important determinants of anticancer drug sensitivity [32].
We found that the proto-oncogene EVI1 not only binds Bcl-xL
promoter but also up regulates its transcriptional activity and
protein expression. We confirmed the occupancy of this site by
EVI1 using ChIP analysis in HT-29/293T cells and also by
EMSA in 293T cells transfected with EVI1. This is an important
finding as other than EVI1 mediated GATA-2 and Pbx1
activation, the proto oncogene has been shown to act as a
repressor. Bcl-xL on the other hand is regulated by several other
transcription factor families, including STATs (signal transducers
and activators of transcription) [33], NF-kB [34], Ets [35], GATA
[24], and HIF-1a [17], suggesting that Bcl-xL is induced by
different transcription mechanisms depending on the cellular
context and the stimulated signals. It is interesting to note that all
Figure 4. Acetylation of EVI1 induces apoptosis in HT-29 cells (Annexin-V-binding assay). A. HT-29 cells transfected with EVI1 specific
siRNA or PCAF-wt or PCAF-DN were cultured for twenty four hours and then 1 mM of plumbagin (Sigma) was added for another twelve hours. After
thirty six hours of transfection, surface exposure of phosphatidyl serine in the apoptotic cells was measured by Annexin-V-PE and 7-AAD, by using the
Annexin-V-PE apoptosis detection kit (BD biosciences, USA) as per the instruction of the manufacturer. Apoptotic cells are Annexin-V positive and 7
AAD negative but dead cells are positive for both. The percentages of cells that are positive for Annexin-V are 15.2, 46.68, 34.72 and 22.28 for HT-29
cells, EVI1 specific siRNA transfected HT-29 cells, PCAF-wt or PCAF-DN transfected HT-29 cells respectively. B. A part of the same transfected cells that
were used for apoptosis assay was checked for the BCL-XL protein expression with Bcl-xL antibody (Imgenex India Pvt. Ltd.) through fluorescence
intensity by FACS. As shown BCL-XL expression was higher in HT-29 cells however BCL-XL expression was reduced when EVI1 siRNA or PCAF was
transfected in the HT-29 cells. Expression of PCAF-DN again increased the BCL-XL expression (p value,0.0001).
doi:10.1371/journal.pone.0025370.g004
Regulation of Bcl-xL by EVI1
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25370of the above factors are normally expressed in one or the other cell
system; however EVI1 is inappropriately up regulated during
oncogenesis. Cells over expressing Bcl-xL mediated by an
oncogene can help in the cell survival following DNA damage
and can potentially accumulate new somatic mutations at higher
frequencies [36]. It was reported earlier that activation of STAT5
can contribute to Bcl-X induction in CML; however STAT5 by
itself is not sufficient. Other pathways including activation through
IL-3 receptor or PI-3K has also been reported. Thus in an
advanced CML case it may so happen that EVI1 acts along with
others for maximum accumulation of BCL-XL protein and thus
blocks apoptosis. The resulting persistence accumulation and
mutations could lead to progression of disease as has been seen in
chronic myeloid leukemia, where EVI1 synergizes with the pre-
existing oncogene (such as BCR-ABL) to give a highly proliferating
and aggressive leukemic clone in a subgroup of CML patients that
progresses to blast crisis. Thus, clearly it will be of interest to
understand how the expression of Bcl-xL can be regulated in
response to the proto-oncogene EVI1 for effective therapeutic
intervention.
An important outcome of our study is the provision of a
mechanism for the role of acetylation in regulating EVI1 activity.
Although all of the transcription factors that bind to Bcl-xL are
acetylated, nothing is known how their acetylated form regulates
Bcl-xL. Acetylation by lysine acetyltransferases like CBP/p300,
PCAF, MYST family modulate the activity of many genes by
modifying the lysine residues of both core histones and
transcription-related factors and thus play an important role in
tumor suppression, apoptosis, cellular proliferation. CBP and
PCAF associate with Ku70 in vivo and inhibit the ability of Ku70 to
suppress Bax-mediated apoptosis, demonstrating that acetylation
negatively regulates the antiapoptotic function of Ku70 in vivo,
thus providing a critical link between acetyltransferase and tumor
suppression [37]. On a separate note, acetylation of FoxO1
activates Bim expression to induce apoptosis in response to HDAC
inhibitor depsipeptide [38], but FoxO3 induced expression of the
cell death gene BIM was not inhibited by treatment of cells with
nicotinamide and TSA [39]. MYST family mediated acetylation
deficient p53 fails to induce apoptosis but not cell cycle arrest as it
can selectively block the transcription of proapoptotic target genes
Figure 5. Acetylation of EVI1 induces apoptosis in HT-29 cells (TUNEL assay). A. HT-29 cells were transfected and treated as above
(Figure 4). After thirty six hours of transfection, cells were stained with TUNEL reagent (BD biosciences, USA) as per the instruction of the
manufacturer. The approximate percentages of cells that are positive for TUNEL are 41, 55, 58 and 28 for HT-29 cells, EVI1 specific siRNA transfected
HT-29 cells, PCAF-wt or PCAF-DN transfected HT-29 cells respectively (p value=0.0036). B. A part of the same transfected cells that were used for
apoptosis assay was checked for the BCL-XL mRNA level through real time PCR. As shown Bcl-xL mRNA level was higher in HT-29 cells however it was
reduced when EVI1 siRNA or PCAF was transfected in the HT-29 cells. Expression of PCAF-DN again increased the Bcl-xL mRNA level (p value=0.0016).
C. Another part of the same transfected cells that were used for apoptosis assay was checked for the BCL-XL protein expression with Bcl-xL antibody
(Imgenex India Pvt. Ltd.) and beta-actin antibody (Santa Cruz) through western blotting. As shown BCL-XL expression was higher in HT-29 cells
however BCL-XL expression was reduced when EVI1 siRNA or PCAF was transfected in the HT-29 cells. Expression of PCAF-DN again increased the
BCL-XL expression. D. The same western blotting data was quantified by Bio-rad gel doc volume analysis method. Figure shows a quantification of
Bcl-xL with respect to the beta actin (p value=0.0039).
doi:10.1371/journal.pone.0025370.g005
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hMDM2 remain unaffected [40]. Any deregulation of acetylation/
deacetylation equilibrium or inappropriate modifications could
lead to different diseases. Previous studies have shown that
reversible acetylation of EVI1 is associated with nuclear speckles
that are known to be associated with different cellular functions
including apoptosis. Here we show decreased transcription of
antiapoptotic targets by acetylated EVI1. The sequence-specific
DNA binding activity of EVI1 was shown to be dramatically
affected by acetylation like in HSF1 and IRF7 [41,42], possibly as
a result of an acetylation induced change in charge. Acetylation
can bring about a change in the apoptosis network by reversing the
apoptosis block induced by EVI1. Additional experiments will also
be needed to determine what signals and proteins promote the
activity of PCAF under anti-/proapoptotic conditions. Our data
clearly shows that acetylated and deacetylated EVI1 divergently
regulates the apoptotic pathway by influencing Bcl-xL. This is very
interesting as ineffective hematopoiesis resulting in peripheral
blood cytopenias is a hallmark of MDS (EVI1 is reported in both
MDS and MDS-AML), and excessive apoptosis of hematopoietic
precursors in the marrow appears to be one of the underlying
mechanisms. It is not well understood how a disease characterized
by excessive apoptosis transforms into one with considerable
apoptosis resistance. Elucidation of EVI1 dependent Bcl-xL
expression may provide a new dimension for understanding
MDS disease progression as disruption of apoptosis pathways may
also allow for damaged cells to survive and acquire the
characteristics of transformed cells. Our results are especially
attractive because it could lead to the development of new
therapeutic drugs that can selectively enhance the enzymatic
activity of specific acetyltransferases that are involved in
acetylation of EVI1. More extensive analysis is underway to
elucidate additional functions of EVI1 that may be regulated by
acetylation.
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